Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$36.34+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.46BP/E 103.8Yield –
Pacira BioSciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Pacira BioSciences's free cash flow for the twelve months ending Jun 30, 2026 was $179.52M, up 53.3% year over year. For fiscal 2025 it was $136.66M, down 23.5% from the year before. The highest annual figure on record is $178.75M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.66M | -23.5% |
| FY2024 | Dec 31, 2024 | $178.75M | +28.1% |
| FY2023 | Dec 31, 2023 | $139.49M | +21.1% |
| FY2022 | Dec 31, 2022 | $115.20M | +44.3% |
| FY2021 | Dec 31, 2021 | $79.85M | +103.5% |
| FY2020 | Dec 31, 2020 | $39.23M | -35.0% |
| FY2019 | Dec 31, 2019 | $60.36M | +75.7% |
| FY2018 | Dec 31, 2018 | $34.36M | – |
| FY2017 | Dec 31, 2017 | -$1.48M | -116.9% |
| FY2016 | Dec 31, 2016 | $8.74M | – |
| FY2015 | Dec 31, 2015 | -$12.27M | -442.8% |
| FY2014 | Dec 31, 2014 | $3.58M | – |
| FY2013 | Dec 31, 2013 | -$56.01M | – |
| FY2012 | Dec 31, 2012 | -$88.39M | – |
| FY2011 | Dec 31, 2011 | -$37.17M | – |
| FY2010 | Dec 31, 2010 | -$31.65M | – |
| FY2009 | Dec 31, 2009 | -$26.35M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.12M | +502.5% |
| Q1 FY2026 | Mar 31, 2026 | $22.96M | -14.7% |
| Q4 FY2025 | Dec 31, 2025 | $43.47M | +40.2% |
| Q3 FY2025 | Sep 30, 2025 | $56.96M | +14.3% |
| Q2 FY2025 | Jun 30, 2025 | $9.32M | -82.0% |
| Q1 FY2025 | Mar 31, 2025 | $26.91M | -41.8% |
| Q4 FY2024 | Dec 31, 2024 | $31.01M | -32.3% |
| Q3 FY2024 | Sep 30, 2024 | $49.83M | +21.4% |
| Q2 FY2024 | Jun 30, 2024 | $51.65M | +28.8% |
| Q1 FY2024 | Mar 31, 2024 | $46.27M | +268.3% |
| Q4 FY2023 | Dec 31, 2023 | $45.79M | +25.3% |
| Q3 FY2023 | Sep 30, 2023 | $41.04M | +9.5% |
| Q2 FY2023 | Jun 30, 2023 | $40.10M | +121.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.56M | -45.6% |
| Q4 FY2022 | Dec 31, 2022 | $36.55M | +160.1% |
| Q3 FY2022 | Sep 30, 2022 | $37.47M | -20.6% |
| Q2 FY2022 | Jun 30, 2022 | $18.07M | -7.7% |
| Q1 FY2022 | Mar 31, 2022 | $23.11M | – |
| Q4 FY2021 | Dec 31, 2021 | $14.05M | -56.4% |
| Q3 FY2021 | Sep 30, 2021 | $47.21M | +47.5% |
| Q2 FY2021 | Jun 30, 2021 | $19.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$992.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $32.26M | +50.7% |
| Q3 FY2020 | Sep 30, 2020 | $32.02M | +91.0% |
| Q2 FY2020 | Jun 30, 2020 | -$24.53M | -218.4% |
| Q1 FY2020 | Mar 31, 2020 | -$516.00K | -134.8% |
| Q4 FY2019 | Dec 31, 2019 | $21.41M | +12.8% |
| Q3 FY2019 | Sep 30, 2019 | $16.76M | +37.7% |
| Q2 FY2019 | Jun 30, 2019 | $20.71M | +87.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.48M | – |
| Q4 FY2018 | Dec 31, 2018 | $18.98M | +60.1% |
| Q3 FY2018 | Sep 30, 2018 | $12.18M | – |
| Q2 FY2018 | Jun 30, 2018 | $11.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.87M | – |
| Q4 FY2017 | Dec 31, 2017 | $11.86M | -4.9% |
| Q3 FY2017 | Sep 30, 2017 | -$8.23M | -205.8% |
| Q2 FY2017 | Jun 30, 2017 | -$1.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.47M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.78M | – |
See a number that looks wrong?